GlassScriptPhysician profile
Karthikeyan Ranganathan
NPI 1013358605
$11,815.82
in general payments reported to CMS, 2019-2025
35 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,933 · 2020: $807 · 2021: $3,134 · 2022: $1,902 · 2023: $1,080 · 2024: $1,495 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,039.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,450.57 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Coroflow |
| Abiomed | $1,377.25 | 2019-2025 | Impella |
| Medtronic, INC. | $1,030.34 | 2021-2025 | Corevalve Evolut R |
| Medtronic Vascular, INC. | $924.96 | 2019 | |
| Philips North America LLC | $738.73 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $703.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $642.75 | 2019-2022 | |
| Inari Medical, INC. | $416.25 | 2021 | |
| Boston Scientific Corporation | $401.74 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $389.97 | 2019-2024 | Lifevest |
| Shockwave Medical, INC | $223.38 | 2022 | |
| Getinge USA Sales, LLC | $210.90 | 2024 | Cardiohelp |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.53 | 2021 | |
| Edwards Lifesciences Corporation | $181.92 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Endotronix, INC. | $180.60 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $175.66 | 2019-2023 | Eliquis, Camzyos |
| Cook Medical LLC | $163.21 | 2019 | |
| Cerus Corporation | $137.17 | 2023-2024 | Intercept Blood System For Platelets |
| Angiodynamics, INC. | $132.19 | 2021 | |
| W. L. Gore & Associates, INC. | $125.00 | 2021 | |
| La Jolla Pharmaceutical Company | $123.47 | 2022 | |
| Vifor Pharma, INC. | $116.98 | 2021 | |
| Penumbra, INC. | $116.83 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.22 | 2020 | |
| Amgen INC. | $100.69 | 2021-2025 | Repatha |
| Cardiovascular Systems INC. | $87.84 | 2020-2021 | |
| Chiesi USA, INC. | $75.13 | 2021 | |
| Cardiva Medical, INC. | $72.98 | 2022 | |
| Novartis Pharmaceuticals Corporation | $71.17 | 2023-2025 | |
| Livanova USA, INC. | $26.73 | 2022 | |
| Bridgebio Pharma, INC. | $26.25 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $24.33 | 2025 | Assure Wcd |
| Mindray Ds USA, INC. | $22.38 | 2023 | Te X, Te7 Max |
| United Therapeutics Corporation | $22.24 | 2024 | Tyvaso |
| Pfizer INC. | $13.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karthikeyan Ranganathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.